OCUL Ocular Therapeutix

Ocular Therapeutixâ„¢ to Report Fourth Quarter and Full Year 2016 Financial Results

BEDFORD, Mass--(BUSINESS WIRE)--

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, on Friday, March 10, 2017. Following distribution of the earnings release via wire services, the Ocular management team will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a general business update.

The live webcast can be accessed by visiting the investor section of Ocular’s website at investors.ocutx.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 77324558. An archive of the webcast will be available until March 24, 2017 on the company’s website.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA (dexamethasone insert), which has completed Phase 3 clinical development for ocular pain and inflammation following ophthalmic surgery, and the Company is pursuing additional indications for DEXTENZA. OTX-TP (sustained release travoprost) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

EN
08/03/2017

Underlying

OCULOcular Therapeutix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Asse...

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025 BEDFORD, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a registrati...

August 12, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and ...

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for both SOL trials Ocular to host Investor Day on Tuesday, September 30, 2025, in New York City Raised gross proceeds of approximately $97 million in June 2025 through existing ATM facility Cash balance o...

August 5, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on...

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, August 5, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2025. Conference Call and Webcast Information: Date: Tuesday, August 5, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1-877...

July 29, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025. 8th Annual OIS Retina Innovation Summit (OIS Retina 2025): Long Beach, CA Company Presentation: Ocular Therapeutix Session: Spotlight on Drug DeliverySession Date/Time: Tuesday, July 29, 2025, 11:00 AM – 12:35 PM PTPresenter: Sanjay Nayak, MBBS, Ph...

July 22, 2025 1 EN
 PRESS RELEASE
Free
OCUL Ocular Therapeu...

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Tra...

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company.  Ocular Therapeutix Logo ...

June 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch